The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2016
At a glance
- Drugs Gadobenic acid (Primary)
- Indications CNS disorders
- Focus Diagnostic use
- Sponsors Bracco Diagnostics
- 18 Jul 2016 Status changed from recruiting to completed.
- 19 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
- 19 Nov 2014 New trial record